Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
1.59
Dollar change
-0.02
Percentage change
-1.24
%
Index- P/E- EPS (ttm)-0.87 Insider Own40.09% Shs Outstand100.02M Perf Week13.57%
Market Cap264.24M Forward P/E- EPS next Y-0.32 Insider Trans0.00% Shs Float99.56M Perf Month-34.30%
Income-114.33M PEG- EPS next Q-0.17 Inst Own15.90% Short Float6.82% Perf Quarter-5.92%
Sales46.74M P/S5.65 EPS this Y41.76% Inst Trans-9.17% Short Ratio7.17 Perf Half Y2.58%
Book/sh-1.73 P/B- EPS next Y36.84% ROA-121.73% Short Interest6.79M Perf Year-79.62%
Cash/sh0.02 P/C67.41 EPS next 5Y- ROE-163.31% 52W Range0.90 - 16.90 Perf YTD-22.06%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-90.59% Beta0.70
Dividend TTM- Quick Ratio0.17 Sales past 5Y14.78% Gross Margin57.58% 52W Low76.65% ATR (14)0.14
Dividend Ex-Date- Current Ratio0.19 EPS Y/Y TTM-386.34% Oper. Margin-225.55% RSI (14)53.96 Volatility8.73% 8.88%
Employees105 Debt/Eq- Sales Y/Y TTM- Profit Margin-244.59% Recom1.00 Target Price6.83
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-0.28% Payout- Rel Volume0.69 Prev Close1.61
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume945.98K Price1.59
SMA2010.67% SMA50-0.71% SMA200-40.59% Trades Volume651,666 Change-1.24%
Date Action Analyst Rating Change Price Target Change
Oct-16-23Initiated B. Riley Securities Buy $4
Oct-13-23Initiated B. Riley Securities Buy $4
Oct-09-23Initiated H.C. Wainwright Buy $12
Mar-27-24 09:00AM
Mar-21-24 09:30AM
Mar-20-24 11:00AM
09:00AM
Mar-19-24 09:00AM
09:00AM Loading…
Mar-18-24 09:00AM
Mar-15-24 02:45PM
09:00AM
Mar-05-24 04:01PM
09:00AM
Mar-04-24 09:00AM
Mar-02-24 03:25PM
Feb-29-24 05:32PM
Feb-28-24 09:00AM
Feb-27-24 09:00AM
04:53PM Loading…
Feb-26-24 04:53PM
09:00AM
Feb-20-24 09:00AM
Jan-08-24 09:00AM
Jan-02-24 09:00AM
Dec-26-23 11:00AM
Dec-20-23 09:00AM
Dec-19-23 09:00AM
Dec-15-23 09:00AM
Dec-12-23 09:00AM
Dec-06-23 09:00AM
Dec-04-23 09:00AM
09:00AM
Dec-01-23 09:00AM
Nov-30-23 09:00AM
09:00AM Loading…
Nov-28-23 09:00AM
Nov-27-23 09:00AM
Nov-22-23 09:00AM
Nov-21-23 09:00AM
Nov-17-23 09:00AM
Nov-15-23 09:00AM
Nov-02-23 09:00AM
09:00AM
Nov-01-23 09:00AM
Oct-27-23 03:38PM
02:05PM
Oct-26-23 06:12AM
Oct-09-23 02:55PM
Oct-07-23 07:27PM
Oct-04-23 12:59PM
Oct-03-23 09:00AM
Sep-27-23 09:00AM
Sep-25-23 09:00AM
Sep-22-23 11:38AM
Sep-21-23 04:05PM
Sep-14-23 09:00AM
Sep-13-23 09:00AM
Sep-12-23 05:34PM
09:00AM
09:00AM
Sep-11-23 09:00AM
Jul-27-23 09:00AM
Jul-21-23 05:53PM
Jul-20-23 09:00AM
Jul-13-23 09:00AM
Jul-05-23 09:00AM
Jun-16-23 09:00AM
Jun-15-23 09:03AM
09:00AM
Jun-01-23 12:28PM
May-31-23 03:16PM
May-22-23 09:00AM
May-14-23 03:00PM
08:09AM
May-05-23 06:08AM
May-04-23 09:00AM
Apr-28-23 02:42PM
09:00AM
Apr-27-23 07:26AM
Apr-25-23 07:30PM
Apr-17-23 09:00AM
Apr-14-23 06:32PM
Apr-13-23 12:25PM
Apr-05-23 05:27PM
Apr-04-23 01:49PM
Mar-27-23 09:00AM
Mar-21-23 09:00AM
Mar-08-23 10:13AM
Feb-27-23 09:00AM
Feb-18-23 08:37PM
Feb-17-23 03:47PM
Feb-16-23 02:40PM
Feb-13-23 03:46PM
Feb-04-23 10:48PM
Feb-03-23 08:59PM
Feb-02-23 01:15PM
Jan-20-23 10:24AM
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.